Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Otsuka’s ADHD Med Hits Mark in PIII Pediatric Trials in US
Otsuka Pharmaceutical’s investigational ADHD drug centanafadine met the primary endpoint in a pair of PIII pediatric trials in the US, according to topline data released by the company on October 27. Detailed results will be published in a scientific journal…
To read the full story
Related Article
- Otsuka’s Centanafadine Accepted for FDA Review with Priority Tag
January 28, 2026
- Otsuka Files Novel ADHD Drug Centanafadine in US
November 26, 2025
- Otsuka’s ADHD Med Hits Primary Goal in US PIII Trials
June 15, 2020
- Otsuka to Buy Neurovance, Gets Its Hands on Non-Stimulant ADHD Med
March 6, 2017
BUSINESS
- Fycompa Generics Head for Summer Launch as Key Patent Expires
June 23, 2026
- ASKA’s Relugolix Combo Hits Primary Goal in Japan PIII Fibroid Study
June 23, 2026
- Rege Nephro Raises 1.22 Billion Yen to Advance ADPKD Drug, iPSC Kidney Program
June 23, 2026
- Japan OTC Drug Market Falls for Third Straight Month in May: Intage
June 23, 2026
- Lilly Japan Names Karla Alcazar as New President
June 22, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…